These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 22740202)

  • 1. Cisplatin-ifosfamide combination chemotherapy in metastatic triple-negative, anthracycline- and taxane-pretreated breast cancer patients; a phase II study.
    Halim A; Wahba H
    J BUON; 2012; 17(2):254-8. PubMed ID: 22740202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Capecitabine/cisplatin doublet in anthracycline and taxane pretreated and HER-2 negative metastatic breast carcinoma patients.
    Ozdemir N; Aksoy S; Sendur MA; Akinci MB; Yazici O; Budakoglu B; Abali H; Oksuzoglu B; Zengin N
    J BUON; 2013; 18(4):831-7. PubMed ID: 24344005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paclitaxel combined with ifosfamide in anthracycline- and docetaxel-pretreated metastatic breast cancer: activity independence of prior docetaxel resistance.
    Moon YW; Sohn JH; Choi HJ; Chang H; Park BW; Kim SI; Park S; Koo JS; Kim YT; Roh JK; Chung HC; Kim JH
    Cancer Chemother Pharmacol; 2010 Aug; 66(3):425-31. PubMed ID: 20012956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemotherapy with paclitaxel, ifosfamide, and cisplatin for the treatment of squamous cell cervical cancer: the experience of Monza.
    Zanetta G; Fei F; Mangioni C
    Semin Oncol; 2000 Feb; 27(1 Suppl 1):23-7. PubMed ID: 10697040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paclitaxel-ifosfamide-cisplatin as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and paclitaxel.
    Polyzos A; Kosmas C; Tsavaris N; Toufexi H; Lagadas A; Gogas H; Giannakopoulos K; Kouraklis G; Griniatsos J; Felekouras E; Tsigris C; Nikiteas N; Papadopoulos O; Giannopoulos A
    Anticancer Res; 2007; 27(3B):1645-51. PubMed ID: 17595790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II study of lipoplatin (liposomal cisplatin)/vinorelbine combination in HER-2/neu-negative metastatic breast cancer.
    Farhat FS; Temraz S; Kattan J; Ibrahim K; Bitar N; Haddad N; Jalloul R; Hatoum HA; Nsouli G; Shamseddine AI
    Clin Breast Cancer; 2011 Dec; 11(6):384-9. PubMed ID: 21993011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment outcomes and clinicopathologic characteristics of advanced triple-negative breast cancer patients].
    Zhang P; Xu BH; Ma F; Li Q; Yuan P; Wang JY; Zhang P
    Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):381-4. PubMed ID: 21875471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline- and/or paclitaxel-containing regimens.
    Ray-Coquard I; Biron P; Bachelot T; Guastalla JP; Catimel G; Merrouche Y; Droz JP; Chauvin F; Blay JY
    Cancer; 1998 Jan; 82(1):134-40. PubMed ID: 9428489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Docetaxel plus cisplatin is effective for patients with metastatic breast cancer resistant to previous anthracycline treatment: a phase II clinical trial.
    Park SH; Cho EK; Bang SM; Shin DB; Lee JH; Lee YD
    BMC Cancer; 2005 Feb; 5():21. PubMed ID: 15723709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
    Klaassen U; Wilke H; Seeber S
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II randomized study of two taxanes and cisplatin for metastatic breast cancer after anthracycline: a final analysis.
    Lin YC; Chang HK; Chen JS; Wang HM; Yang TS; Liaw CC
    Jpn J Clin Oncol; 2007 Jan; 37(1):23-9. PubMed ID: 17172351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An open-labeled phase II trial of docetaxel in combination with cisplatin as first-line cytotoxic therapy for anthracycline-naive patients with metastatic breast cancer.
    Lin YC; Chang HK; Shen WC; Chen JS; Wang HM
    Anticancer Drugs; 2007 Nov; 18(10):1213-9. PubMed ID: 17893523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group.
    Schmoll HJ; Kollmannsberger C; Metzner B; Hartmann JT; Schleucher N; Schöffski P; Schleicher J; Rick O; Beyer J; Hossfeld D; Kanz L; Berdel WE; Andreesen R; Bokemeyer C;
    J Clin Oncol; 2003 Nov; 21(22):4083-91. PubMed ID: 14568987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of paclitaxel, ifosfamide, and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
    Shin DM; Glisson BS; Khuri FR; Hong WK; Lippman SM
    Semin Oncol; 1998 Apr; 25(2 Suppl 4):40-4; discussion 45-8. PubMed ID: 9578061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design.
    Kassam F; Enright K; Dent R; Dranitsaris G; Myers J; Flynn C; Fralick M; Kumar R; Clemons M
    Clin Breast Cancer; 2009 Feb; 9(1):29-33. PubMed ID: 19299237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Docetaxel and cisplatin combination chemotherapy in metastatic breast cancer patients with previous exposure to anthracyclines.
    Ahn JH; Kim SB; Sohn HJ; Lee JS; Kang YK; Kun Kim W
    Breast; 2005 Aug; 14(4):304-9. PubMed ID: 16085237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Docetaxel-ifosfamide combination in patients with HER2-non-overexpressing advanced breast cancer failing prior anthracyclines.
    Kosmas C; Tsavaris N; Malamos N; Tsakonas G; Gassiamis A; Polyzos A; Mylonakis N; Karabelis A
    Invest New Drugs; 2007 Oct; 25(5):463-70. PubMed ID: 17370037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carboplatin and gemcitabine combination in metastatic triple-negative anthracycline- and taxane-pretreated breast cancer patients: a phase II study.
    Maisano R; Zavettieri M; Azzarello D; Raffaele M; Maisano M; Bottari M; Nardi M
    J Chemother; 2011 Feb; 23(1):40-3. PubMed ID: 21482494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Triple-negative breast cancer: analysis of patients diagnosed and/or treated at the Masaryk Memorial Cancer Institute between 2004 and 2009].
    Svoboda M; Navrátil J; Fabian P; Palácová M; Gombošová J; Slámová L; Princ D; Syptáková B; Kudláček A; Bílek O; Pospíšil P; Kazda T; Grell P; Poprach A; Selingerová I; Nenutil R; Juráček J; Héžová R; Slabý O; Vyzula R
    Klin Onkol; 2012; 25(3):188-98. PubMed ID: 22724568
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of docetaxel, ifosfamide and cisplatin (DIP) as a potential salvage chemotherapy for metastatic urothelial carcinoma.
    Kakutani S; Fukuhara H; Taguchi S; Nagata M; Niimi A; Hattori M; Miyazaki H; Fujimura T; Nakagawa T; Kume H; Igawa Y; Homma Y
    Jpn J Clin Oncol; 2015 Mar; 45(3):281-5. PubMed ID: 25425701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.